The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Fetal hemoglobin in sickle cell anemia
Open accessAbstract
Fetal hemoglobin (HbF) is the major genetic modulator of the hematologic and clinical features of sickle cell disease, an effect mediated by its exclusion from the sickle hemoglobin polymer. Fetal hemoglobin genes are genetically regulated, and the level of HbF and its distribution among sickle erythrocytes is highly variable. Some patients with sickle cell disease have exceptionally high levels of HbF that are associated with the Senegal and Saudi-Indian haplotype of the HBB-like gene cluster; some patients with different haplotypes can have similarly high HbF. In these patients, high HbF is associated with generally milder but not asymptomatic disease. Studying these persons might provide additional insights into HbF gene regulation. HbF appears to benefit some complications of disease more than others. This might be related to the premature destruction of erythrocytes that do not contain HbF, even though the total HbF concentration is high. Recent insights into HbF regulation have spurred new efforts to induce high HbF levels in sickle cell disease beyond those achievable with the current limited repertory of HbF inducers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HbF is variably increased in nearly all HbS homozygotes.4”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BCL11A is a repressor of HbF gene expression.”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 1×
“Three possible mechanisms have been proposed to explain the increased HbF associated with these large deletions: (1) the deletion of regulatory sequences affecting HBG expression, (2) juxtaposition of enhancers of HBG normally located downstream of HBB, and (3) LCR interactions with HBG resulting from deletion of HBB.”
Self-citationEffect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Cerebrovascular accidents in sickle cell disease: rates and risk factors.
(1998) · PubMed · doi:10.1182/blood.v91.1.288 · Cited by 1,694
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N., Cannon, R. O., Schechter, A. N., & Gladwin, M. T. (2002) · Nature Medicine · doi:10.1038/nm1202-799 · Cited by 1,330
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., et al. (2002) · Nature Medicine · doi:10.1038/nm799 · Cited by 1,097
Weatherall, D. J., & Clegg, J. B. (2001) · Wiley eBooks · doi:10.1002/9780470696705 · Cited by 1,069
Steinberg, M. H., Barton, F., Castro, O., Pegelow, C. H., Ballas, S. K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1645 · Cited by 931
Self-citationHuman Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A
Sankaran, V. G., Menne, T. F., Xu, J., Akie, T. E., Lettre, G., Van Handel, B., Mikkola, H. K. A., Hirschhorn, J. N., Cantor, A. B., & Orkin, S. H. (2008) · Science · doi:10.1126/science.1165409 · Cited by 919
Kato, G. J., Gladwin, M. T., & Steinberg, M. H. (2007) · Blood Reviews · doi:10.1016/j.blre.2006.07.001 · Cited by 876
Self-citation(1973) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1973.tb111034.x · Cited by 811
Research works printed but not linked: 5
- Rodgers, 2001, Pharmacologic treatment of sickle cell disease and thalassemia: the augmentation of fetal hemoglobin., 1028
- Nagel, 1994, Origins and dispersion of the sickle gene., 353
- Farrell, A 3-bp deletion between transcription factor binding motifs in the HBS1L-MYB intergenic region on chromosome 6q23 is associated with HbF expression [published online ahead of print March 8, 2011]., Blood
- Wood, 2001, Hereditary persistence of fetal hemoglobin and δβ-thalassemia., 356
- Sutton, 1998, Absence of cross-resistance to the Hb F stimulating activities of butyrate and hydroxyurea., Blood, 92, 694a
Cited by
Piel, F. B., Steinberg, M. H., & Rees, D. C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510865 · Cited by 1,488
Self-citationIntravascular hemolysis and the pathophysiology of sickle cell disease
Kato, G. J., Steinberg, M. H., & Gladwin, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89741 · Cited by 748
Self-citationPiel, F. B., Steinberg, M., & Rees, D. C. (2016) · Spiral (Imperial College London) · doi:10.1056/nejmc1706325#sa6 · Cited by 659
Self-citationCRISPR Gene Therapy: Applications, Limitations, and Implications for the Future
Uddin, F., Rudin, C. M., & Sen, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01387 · Cited by 581
Traxler, E. A., Yao, Y., Wang, Y.-D., Woodard, K. J., Kurita, R., Nakamura, Y., Hughes, J. R., Hardison, R. C., Blobel, G. A., Li, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4170 · Cited by 366
Metadata
- Authors
- Akinsheye, I., Alsultan, A., Solovieff, N., Ngo, D., Baldwin, C. T., Sebastiani, P., Chui, D. H. K., & Steinberg, M. H.
- Affiliations
- Boston University (US)
- King Saud University (SA)
- Department of Biostatistics, Boston University School of Public Health, Boston, MA
- Corresponding author
- Akinsheye, Idowu
- Alsultan, Abdulrahman
- Solovieff, Nadia
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2011-07-07
- Volume
- 118
- Issue
- 1
- Pages
- 19-27
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC3139383
- OpenAlex
- W1990599619
- Semantic Scholar
- 2ab0d3df4c8d35938e22013aefcea18ae78cce49
- Cited by
- 553
- References
- 114
- Citations by year
- 2026: 20 · 2025: 39 · 2024: 52 · 2023: 31 · 2022: 48 · 2021: 48 · 2020: 44 · 2019: 44 · 2018: 40 · 2017: 31 · 2016: 50 · 2015: 32 · 2014: 31 · 2013: 16 · 2012: 20
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL068970, R21HL080463, RC2 HL101211, R01HL070735)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK069646)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Keywords
- fetal hemoglobin, sickle cell disease, erythrocyte hemolysis, disease severity
- MeSH terms
- Anemia, Sickle Cell, Erythrocytes, Fetal Hemoglobin, Haplotypes, Humans, Severity of Illness Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fetal hemoglobin in sickle cell anemia. https://app.cochat.ai/papers/10.1182/blood-2011-03-325258
- The paper
- Akinsheye, I., Alsultan, A., Solovieff, N., Ngo, D., Baldwin, C. T., Sebastiani, P., Chui, D. H. K., & Steinberg, M. H. (2011). Fetal hemoglobin in sickle cell anemia. Blood. https://doi.org/10.1182/blood-2011-03-325258
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.